New Diabetes Therapies in Roche's Top Prospect for 2014
Diabetes treatment drug information is always a pertinent matter for patients as well as investors. Roche released a statement today focusing on their future plans of innovative diabetes treatment drugs and the various ways that diabetes can be diagnosed and cared for. The statement is in reference to their first investor conference after joining with Genentech.
“Roche is uniquely positioned to deliver sustainable, long-term growth. Our success derives from the diversity of approaches applied by our Pharmaceuticals and Diagnostics R&D centres, which offer outstanding scientific excellence and an unparalleled breadth and depth of expertise in translational medicine and clinical science,” stated Severin Schwan, CEO of Roche.
Ten new molecular entities (NMEs) offered by the company are aiming for first or best-in-class medicines. Many of them focus on cancer, metabolic and autoimmune diseases and central nervous system disorders (CNS).
“In order to develop more efficacious and safer medicines, we pursue a seamless cooperation between our Pharmaceuticals and Diagnostics units from research through to the market to implement Personalised Healthcare as an integral part of our drug development efforts.”
Two late-stage development of two new diabetes treatment drugs are being targeted for patients with unmet medical needs. Taspoglutide and dalcetrapib are both being planned for submission in 2011 and 2013. Taspoglutdie is the for type 2 diabetes treatment and dalcetrapib is for atherosclerosis in high-risk cardiovascular patients.
Aleglitazar has also started recruiting participants for a phase III study. The drug is mainly for high-risk type 2 diabetes patients who have experience cardiac events. The new treatment aims to reduce morbidity and mortality in those patients.
Roche outlined the 10 new molecular entities in ongoing or planned late-stage studies, all with a market potential of either “first-in-class” or “best-in-class.” Aleglitazar and taspoglutide are the only ones listed specifically for type 2 diabetes.
Roche is based in Switzerland and is a leader in pharmaceuticals and diagnostics. They claim to be a pioneer in diabetes management and are looking to impress investors and type 2 diabetes patients with their future portfolio that is already in the works.